Purpose. To study the effectiveness of the use of the drug retinalamin in the complex treatment of patients with glaucomatous optical neuropathy (GON) and to compare the results with traditional means of treatment. Material and methods. A study of 70 patients (114 eyes), whose average age was 66.7+ 6.2 years old, suffered from POAG with compensated I0P. The diagnosis of the disease was made on the basis of anamnesis, clinical and instrumental studies. All patients studied were divided into 2 groups. Results. Treatment in both studied groups showed a positive effect on the improvement of biochemical parameters. So, the speed of products lipid peroxidation accumulation decreased from initial by 75.0% and 53.4%, for 77.2%
and 43.3%, for 73.8 and 60.2% according to the l-lll stages of POUG (P<0.001). Conclusion. The use of Retinalamin in the complex treatment of patients with glaucomatous optical neuropathy has an antioxidant effect, reduces the activity of PA2 and the level of MSM in patients with GON.
